NASDAQ: NEUP
Neuphoria Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for NEUP

Based on 2 analysts offering 12 month price targets for Neuphoria Therapeutics Inc

Min Forecast
$21.00+38.43%
Avg Forecast
$28.00+84.57%
Max Forecast
$35.00+130.72%

Should I buy or sell NEUP stock?

Based on 2 analysts offering ratings for Neuphoria Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NEUP's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NEUP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NEUP stock forecasts and price targets.

NEUP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-11
lockedlocked$00.00+00.00%2025-08-26

1 of 1

Forecast return on equity

Is NEUP forecast to generate an efficient return?

Company
-25.82%
Industry
93.13%
Market
-61.61%
NEUP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NEUP forecast to generate an efficient return on assets?

Company
-17.16%
Industry
35.76%
NEUP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NEUP earnings per share forecast

What is NEUP's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.85

NEUP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NEUP$15.17$28.00+84.57%Strong Buy
BCAB$0.74N/AN/A
BTAI$2.46$26.67+984.02%Buy
MURA$2.07N/AN/A
PLUR$4.35$12.00+175.86%Strong Buy

Neuphoria Therapeutics Stock Forecast FAQ

Is Neuphoria Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: NEUP) stock is to Strong Buy NEUP stock.

Out of 2 analysts, 1 (50%) are recommending NEUP as a Strong Buy, 1 (50%) are recommending NEUP as a Buy, 0 (0%) are recommending NEUP as a Hold, 0 (0%) are recommending NEUP as a Sell, and 0 (0%) are recommending NEUP as a Strong Sell.

If you're new to stock investing, here's how to buy Neuphoria Therapeutics stock.

What is NEUP's earnings growth forecast for 2026-2026?

(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16%.

Neuphoria Therapeutics's earnings in 2025 is -$241,589.

In 2026, NEUP is forecast to generate -$4,361,584 in earnings, with the lowest earnings forecast at -$4,361,584 and the highest earnings forecast at -$4,361,584.

What is NEUP's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: NEUP) forecast ROE is -25.82%, which is considered weak.

What is NEUP's Price Target?

According to 2 Wall Street analysts that have issued a 1 year NEUP price target, the average NEUP price target is $28.00, with the highest NEUP stock price forecast at $35.00 and the lowest NEUP stock price forecast at $21.00.

On average, Wall Street analysts predict that Neuphoria Therapeutics's share price could reach $28.00 by Sep 11, 2026. The average Neuphoria Therapeutics stock price prediction forecasts a potential upside of 84.57% from the current NEUP share price of $15.17.

What is NEUP's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: NEUP) Neuphoria Therapeutics's current Earnings Per Share (EPS) is -$0.15. In 2026, NEUP's EPS is forecast to hit -$1.85 (min: -$1.85, max: -$1.85).

What is NEUP's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: NEUP) forecast ROA is -17.16%, which is lower than the forecast US Biotechnology industry average of 35.76%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.